Transition of a clinical trial into translational research: The prostate cancer prevention trial experience

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1523-1533

  Goodman, Phyllis J ^a   Tangen, Catherine M ^a   Kristal, Alan R ^b   Thompson, Ian M ^c   Lucia, M Scott ^d   Platz, Elizabeth A ^e   Figg, William D ^f   Hoque, Ashraful ^g   Hsing, Ann ^f   Neuhouser, Marian L ^b   Parnes, Howard L ^f   Reichardt, Juergen K V ^h   Santella, Regina M ⁱ   Till, Cathee ^a   Lippman, Scott M ^g  

^a SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

CANCER PREVENTION; CANCER RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DNA REPAIR; DRUG EFFICACY; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 78650353461     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0256     Document Type: Note

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA A Cancer J Clin 2009;59:225-49.
2. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst, 2006:98: 529-34.
3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
4. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-81.
5. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
6. Cohen YC, Liu KS, Heyden NL, Anderson KM, Daifotis AG, Gann PH, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74.
7. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res 2008;1:182-6.
8. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202.
9. Leiberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, et al. Executive summary of the National Cancer Institute workshop: highlights and recommendations. Urology 2001;57:4-27.
10. Isaacs WB, De Marzo AM, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2:113-6.
11. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
12. Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. N Engl J Med 2003;349:366-81.
13. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33.
14. Ross RK, Schottenfeld D. Prostate cancer. In: Cancer Epidemiology and Prevention. Schottenfeld D, Fraumeni J, editors. New York: Oxford University Press; 1996:1180-206.
15. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, et al. Androgen metabolismand prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-504.
16. Makridakis N, Reichardt JKV. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol 2004;171:S25-9. (Pubitemid 38090418)
17. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-40.
18. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008;1(3):167-73.
19. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with prostate-specific antigen level ≥4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
20. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic Variants. Cancer Prev Res 2009;2(7):617-24.
21. Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009:301(1):39-51.